Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: Phase 1 results and long-term follow-up

Blood

Volumn 131, Issue 21, 2018, Pages 2331-2334

  Kreitman, Robert J ^a   Tallman, Martin S ^b   Robak, Tadeusz ^c   Coutre, Steven ^d   Wilson, Wyndham H ^e   Stetler Stevenson, Maryalice ^a   FitzGerald, David J ^a   Santiago, Linda ^f   Gao, Guozhi ^f   Lanasa, Mark C ^f   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Metabolism Branch   (United States)

^f MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXETUMOMAB PASUDOTOX; PENTOSTATIN; RITUXIMAB; ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; EXOTOXIN;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE DURATION; DISEASE ERADICATION; DISEASE EXACERBATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; LONG TERM CARE; MALE; MINIMAL RESIDUAL DISEASE; MINIMAL RESIDUAL HAIRY CELL LEUKEMIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEX RATIO; SPLEEN SIZE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR IMMUNOGENICITY; TUMOR VOLUME; DRUG MONITORING; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC);

ADULT; AGED; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG MONITORING; EXOTOXINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; TREATMENT OUTCOME;

EID: 85047869117     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-09-803072     Document Type: Article

References (13)

1. Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012;30(15):1822-1828.
2. Jasper GA, Arun I, Venzon D, et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom. 2011; 80B(2):83-90.
3. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988.
4. Böttcher S, Ritgen M, Kneba M. Flow cyto-metric MRD detection in selected mature B-cell malignancies. In: Küppers R, ed. Lymphoma. Methods Molecular Biology (Methods and Protocols). Vol 971. Totowa, NJ: Humana Press;2013:149-174.
5. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001; 345(4):241-247.
6. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005;23(27): 6719-6729.
7. Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009;27(18): 2983-2990.
8. Kreitman RJ, Wilson WH, Stetler-Stevenson M, et al. High complete remission rate in chemotherapy-refractory classic or variant hairy cell leukemia induced by the anti-CD22 recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) [abstract]. Blood. 2000;96: 577a.
9. Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373(18): 1733-1747.
10. Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W, Kreitman RJ. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res. 2013;19(22):6313-6321.
11. Ravandi F, O’Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011; 118(14):3818-3823.
12. Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107(12): 4658-4662.
13. Else M, Dearden CE, Matutes E, et al. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. Leuk Lymphoma. 2011;52(suppl 2):75-78.